Study of Pamidronate for the Prevention of Heterotopic Ossification
NCT00262392
·
clinicaltrials.gov ↗
NA
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Heterotopic Ossification
Interventions
DRUG:
Pamidronate (AREDIA)
Sponsor
University Hospital, Basel, Switzerland
Collaborators
[object Object]